Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Osteoprotegerin (OPG) is a recently identified cytokine that acts as a decoy receptor for the receptor activator of NF kappa B ligand. OPG has been shown to be an important inhibitor of osteoclast differentiation and activation in rodent models. Estrogen is known to suppress bone resorption, and the action of estrogen on bone may be mediated by OPG. The relationship between endogenous estrogen and circulating OPG levels and bone status in human populations is unclear. Thus, the aim of this study was to investigate the relationship between biochemical markers of bone turnover and bone density and circulating OPG and endogenous estradiol levels in a population-based cohort of postmenopausal women. Subjects were 180 women ages 55-91 yr (mean age, 67 yr). Serum estradiol was measured using an auto-analyzer. Serum concentrations of OPG were determined by ELISA. Markers of bone formation and resorption were measured by standard methods. Bone mineral density at total body, total hip, femoral neck, and lumbar spine was measured by dual energy x-ray absorptiometry. There was a significant inverse relationship between estradiol and all bone turnover markers (r-values from -0.46 to -0.23; P < 0.05). Serum estradiol was positively related to absolute bone density at all sites and to change in bone density at the hip and femoral neck by univariate analysis (r-values from 0.15-0.29; P < 0.05). We observed a weak inverse association between OPG and serum-based bone turnover markers (r-values -0.18 and -0.16; P < 0.05). There was a significant positive relationship between OPG and bone mineral density at total body, total hip, and femoral neck (r-values from 0.17-0.2; P < 0.05) by univariate analysis, which was lost after adjustment for age and body mass index. There was a significant weak positive relationship between circulating OPG and serum estradiol (r = 0.18; P < 0.02). We observed no significant relationships between OPG and bone turnover markers measured in urine. We conclude that the variation in circulating endogenous estradiol levels is an important factor contributing to levels of bone turnover and bone density at the menopause. Our observations also suggest that circulating levels of OPG may reflect OPG activity in bone and are related to circulating endogenous levels of estradiol. We have previously reported high levels of variability in urine markers of bone resorption, and we suggest that this could account for the absence of a significant association between these markers and circulating OPG.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Serum OPG levels have been found to be positively related to BMD (375, 379), negatively related to BMD (374, 383), or unrelated to BMD (372, 373) in postmenopausal women.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [375]
In the citing paper
“Age appears to be a major factor influencing OPG levels in nearly all studies (372-377).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [375]
In the citing paper
“the evidence is conflicting about an association between markers of bone turnover and circulating OPG because some studies report an association (154,372,375) or an association only among osteoporotic women (384), and others report no association (373,379).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [375]
In the citing paper
“Residual estrogen levels after the menopause correlate with bone density and fracture risk, yet the relationship of estrogen levels with serum OPG levels in postmenopausal women has been inconsistent across studies, with some supporting a weak relationship (375) and others no relationship (373, 379) or a negative correlation (381).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [375]
Citations
Cites
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · cited 1×
“The mean age of this group at the 5-yr visit was 67 yr (8).”
BackgroundYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228 · cited 1×
“in transgenic mice designed to overexpress OPG, which develop osteopetrosis (8, 11).”
BackgroundIsolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.
Tsuda, E., Goto, M., Mochizuki, S.-I., Yano, K., Kobayashi, F., Morinaga, T., & Higashio, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6603 · Cited by 787 · cited 1×
“The discovery of OPG in 1997 has enhanced our understanding of the way in which the processes of bone remodeling are regulated (8, 9 ). In vitro and animal studies have unambiguously revealed the role of OPG as a decoy receptor for receptor activator of NFB ligand (RANKL), neutralizing the effect of RANKL on the diffe…”
BackgroundSevere osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775 · cited 5×
“• Circulating Estradiol and OPG J Clin Endocrinol Metab, October 2002, 87(10):4470–4475 4471”
BackgroundInfluentialGarnero, P., Sornay-Rendu, E., Claustrat, B., & Delmas, P. D. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1526 · Cited by 709
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 2×
“osteoprotegerin (OPG) in human osteoblast-like cells (7).”
BackgroundRole of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586
Browner, W. S., Lui, L.-Y., & Cummings, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7192 · Cited by 506 · cited 3×
“(18), there was no relationship between OPG and bone density.”
BackgroundThe effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484 · cited 1×
“OPG has also been administered as a therapeutic agent, resulting in a dramatic reduction in bone turnover state, but little is known of its long-term effect on bone density (15).”
BackgroundEpidemiology of Vertebral Fractures
Schousboe, J. T. (2016) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.08.004 · Cited by 451
Cited by
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 988
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Primary osteoporosis in postmenopausal women
Ji, M., & Yu, Q. (2015) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2015.02.006 · Cited by 436
“After 4e8 years, the second phase exhibits a persistent, slower loss of both trabecular and cortical bone, and is mainly attributed to reduced bone formation.(11) This is age related bone loss, which is the only phase that also happens in men.”
BackgroundEastell, R., Adams, J. E., Coleman, R. E., Howell, A., Hannon, R. A., Cuzick, J., Mackey, J. R., Beckmann, M. W., & Clack, G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0726 · Cited by 407
Self-citationThe role of the immune system in the pathophysiology of osteoporosis
Clowes, J. A., Riggs, B. L., & Khosla, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00334.x · Cited by 359
“The relationship between OPG and BMD is equally mixed with negative (53), positive (58), and non-significant effects (54, 56, 57).”
BackgroundResultBone Remodeling in Post-menopausal Osteoporosis
Lerner, U. H. (2006) · Journal of Dental Research · doi:10.1177/154405910608500703 · Cited by 347
“Although serum analyses of OPG are complicated by the fact that OPG is ubiquitously expressed, another study showed that OPG serum levels were positively correlated with 17 -estradiol and bone mineral density (Rogers et al., 2002).”
Eastell, R., Hannon, R. A., Cuzick, J., Dowsett, M., Clack, G., & Adams, J. E. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060508 · Cited by 325
Self-citationBone turnover markers: use in osteoporosis
Naylor, K., & Eastell, R. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.86 · Cited by 262
Self-citationThe OPG/RANKL/RANK system in metabolic bone diseases.
Hofbauer, L. C., Kühne, C. A., & Viereck, V. (2004) · PubMed · Cited by 311
Vega, D., Maalouf, N. M., & Sakhaee, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0646 · Cited by 246
Osteoprotegerin as a Predictor of Coronary Artery Disease and Cardiovascular Mortality and Morbidity
Venuraju, S. M., Yerramasu, A., Corder, R., & Lahiri, A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.013 · Cited by 237
“(46) described a weak positive association of lasma OPG levels with estradiol, whereas Khosla et al.”
BackgroundReid, D. M., Doughty, J., Eastell, R., Heys, S. D., Howell, A., McCloskey, E. V., Powles, T., Selby, P., & Coleman, R. E. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.007 · Cited by 228
Self-citationRogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
“The effect of intermittent PTH therapy on serum OPG has been investigated in women with glucocorticoid-induced osteoporosis (107).”
BackgroundInfluentialSelf-citationGoëb, V., & Anne-Priscille, T. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s10153 · Cited by 179
“In some studies, no association was found between BMD and OPG, 21,39,42,43 whereas other works demonstrated a significant inverse correlation between OPG and BMD, 44 notably in postmenopausal women without any hormone replacement therapy.”
Pathophysiological roles of osteoprotegerin (OPG)
Reid, P., & Holen, I. (2008) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2008.06.004 · Cited by 143
Morabito, N., Gaudio, A., Lasco, A., Atteritano, M., Pizzoleo, M. A., Cincotta, M., La Rosa, M., Guarino, R., Meo, A., & Frisina, N. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040113 · Cited by 127
“,((27)) we found no significant relationships between OPG and urinary bone turnover markers.”
BackgroundInfluentialSowers, M. R., Zheng, H., Greendale, G. A., Neer, R. M., Cauley, J. A., Ellis, J., Johnson, S., & Finkelstein, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4113 · Cited by 127
“The European Vertebral Osteoporosis Study (EVOS) reported a negative association between serum estradiol levels and bone turnover markers in women under the age of 65 years, although this study did not examine women during the menopause transition (44).”
BackgroundLocal Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption
Cawley, K. M., Bustamante-Gomez, N. C., Guha, A. G., MacLeod, R. S., Xiong, J., Gubrij, I., Liu, Y., Mulkey, R., Palmieri, M., Thostenson, J. D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108052 · Cited by 114
“Circulating OPG levels do not consistently correlate with bone mass or the rate of bone remodeling in human studies (Khosla et al., 2002; Rogers and Eastell, 2005; Rogers et al., 2002; Sarink et al., 2019).”
Yang, J. L., Hodara, E., Sriprasert, I., Shoupe, D., & Stanczyk, F. Z. (2024) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002407 · Cited by 121
Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.
Indridason, O. S., Franzson, L., & Sigurdsson, G. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1699-x · Cited by 107
“For example, no association [12], an inverse relationship [13], and a positive correlation [9] have been found between OPG and estrogen levels in women.”
BackgroundResultMezquita-Raya, P., de la Higuera, M., García, D. F., Alonso, G., Ruiz-Requena, M. E., de Dios Luna, J., Escobar-Jiménez, F., & Muñoz-Torres, M. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1844-1 · Cited by 98
“[13] described a borderline correlation of OPG with bALP and serum CTx levels, but not with IFDPD (immunoreactive free deoxypyridinoline) and NTx (urinary crosslinked N-telopeptides of type I collagen).”
BackgroundInfluentialRole of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders
Workgroup, O. B. O. T. E. R. O. (., Carrillo-López, N., Martínez-Arias, L., Fernández-Villabrille, S., Ruiz-Torres, M. P., Dusso, A., Cannata-Andía, J. B., Naves-Díaz, M., & Panizo, S. (2021) · Calcified Tissue International · doi:10.1007/s00223-020-00803-2 · Cited by 91
Naylor, K. E., Rogers, A., Fraser, R. B., Hall, V., Eastell, R., & Blumsohn, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030486 · Cited by 84
“(33) reported a weak, but significant, positive relationship between OPG and both BMD and E2 in postmenopausal women.”
BackgroundSelf-citationStein, N. C., Kreutzmann, C., Zimmermann, S.-P., Niebergall, U., Hellmeyer, L., Goettsch, C., Schoppet, M., & Hofbauer, L. C. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080203 · Cited by 80
“Serum OPG levels in patients with osteoporosis have been shown to be elevated and are thought to represent a compensatory response to limit exaggerated bone resorption,((6)) although other studies have yielded ambiguous results.((7)) The OPG/RANKL/RANK system is es-”
ResultWang, Q., Nicholson, P., Suuriniemi, M., Lyytikäinen, A., Helkala, E., Alén, M., Suominen, H., & Cheng, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031113 · Cited by 91
Gannagé‐Yared, M., Fares, F., Semaan, M., Khalife, S., & Jambart, S. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02522.x · Cited by 76
Cai, K., Hou, Y., Hu, Y., Li, Z., Luo, Z. Y., Shi, Y., Lai, M., Yang, W., & Liu, P. (2011) · Small · doi:10.1002/smll.201101170 · Cited by 80
Stern, A., Laughlin, G. A., Bergstrom, J., & Barrett-Connor, E. L. (2007) · European Journal of Endocrinology · doi:10.1530/eje-06-0753 · Cited by 81
“BMD in women who were not using estrogen is concordant with five of six previous studies (3, 11, 14 , 16, 21, 28).”
ResultSignaling Axis in Osteoclast Biology and Therapeutic Targeting in the RANKL/RANK/OPG System
Tanaka, S. (2007) · American Journal of Nephrology · doi:10.1159/000106484 · Cited by 84
Oh, K. W., Rhee, E. J., Lee, W. Y., Kim, S. W., Baek, K. H., Kang, M. I., Yun, E. J., Park, C. Y., Ihm, S. H., Choi, M. G., et al. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02179.x · Cited by 73
Martini, G., Gennari, L., Merlotti, D., Salvadori, S., Franci, M. B., Campagna, S., Avanzati, A., De Paola, V., Valleggi, F., & Nuti, R. (2007) · Bone · doi:10.1016/j.bone.2006.08.003 · Cited by 72
“Moreover there are discordant data about the relationships between serum OPG, RANKL and markers of bone turnover ranging from a significant association to no relationship [7,10–13].”
BackgroundLiu, J., Zhao, H., Ning, G., Zhao, Y. J., Chen, Y., Zhang, Z., Sun, L., Xu, M.-Y., & Chen, J. L. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0007-2 · Cited by 76
Attia, E. A. S., Khafagy, A. H., Abdel-Raheem, S. M., Ahmed, S. F., & Saad, A. A. (2010) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2010.04600.x · Cited by 74
Ueland, T., Bollerslev, J., Wilson, S. G., Dick, I. M., Islam, A. F. M., Mullin, B. H., Devine, A., & Prince, R. L. (2006) · Bone · doi:10.1016/j.bone.2006.06.022 · Cited by 71
“Our findings showing a lack of relationship between serum OPG and fracture frequency or bone mass are in accordance with some studies [35–37] while others demonstrate a significant independent association [12].”
ResultTauchmanovà, L., Colao, A. A. L., Lombardi, G., Rotoli, B., & Selleri, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2870 · Cited by 69
Osteoporosis and inflammatory bowel disease
Bernstein, C. N., & Leslie, W. D. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01876.x · Cited by 76
Long-term effects of aromatase inhibitors on bone
Eastell, R., & Hannon, R. A. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.04.009 · Cited by 74
Self-citationvon Tirpitz, C., Klaus, J., Steinkamp, M., Hofbauer, L. C., Kratzer, W., Mason, R., Boehm, B. O., Adler, G., & Reinshagen, M. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01448.x · Cited by 66
Arterial Calcifications Seen on Mammograms: Cardiovascular Risk Factors, Pregnancy, and Lactation
Maas, A. H. E. M., van der Schouw, Y. T., Beijerinck, D., Deurenberg, J. J. M., Mali, W. P. T. M., & van der Graaf, Y. (2006) · Radiology · doi:10.1148/radiol.2401050170 · Cited by 64
Serum Osteoprotegerin Is Increased in Crohnʼs Disease: a Population-Based Case Control Study
Bernstein, C. N., Sargent, M. J., & Leslie, W. D. (2005) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000164015.60795.ca · Cited by 67
“Others have found a lack of correlation between serum OPG with bone mineral density.(16,19,23,24)”
BackgroundOh, E. S., Rhee, E.-J., Oh, K. W., Lee, W. Y., Baek, K. H., Yoon, K. H., Kang, M. I., Yun, E. J., Park, C. Y., Choi, M. G., et al. (2005) · Metabolism · doi:10.1016/j.metabol.2004.08.005 · Cited by 61
Increased RANKL/OPG mRNA Ratio in Iliac Bone Biopsies From Women with Hip Fractures
Abdallah, B. M., Stilgren, L. S., Nissen, N., Kassem, M., Jørgensen, H. R. I., & Abrahamsen, B. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-0074-4 · Cited by 60
“Accordingly, treatment with OPG potently blocks bone resorption in postmenopausal women [8], but the relationship between endogenous serum OPG levels and bone mineral density (BMD) is unclear, as both positive and negative associations have been reported in the literature [ 9 , 10].”
ResultEviö, S., Tiitinen, A., Laitinen, K., Ylikorkala, O., & Välimäki, M. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030198 · Cited by 59
“is inversely related to age (36), it can be anticipated that”
BackgroundBone Physiology, Disease and Treatment: Towards Disease System Analysis in Osteoporosis
Post, T. M., Cremers, S. C. L. M., Kerbusch, T., & Danhof, M. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318150-000000000-00000 · Cited by 74
Zarrabeitia, M. T., Hernández, J. L., Valero, C., Zarrabeitia, A., García‐Unzueta, M. T., Amado, J. A., González-Macías, J., & Riancho, J. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500699 · Cited by 54
“In some cross-sectional studies, a relationship has been found between serum estrogens and bone mass ( 5 ).”
BackgroundTrofimov, S., Pantsulaia, I., Kobyliansky, E., & Livshits, G. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500305 · Cited by 51
“For instance, there is evidence from in vitro studies that ESTR stimulates the expression of OPG (24), while in vivo studies have evinced a positive correlation between serum OPG and ESTR levels in both sexes (12, 14 ).”
Aromatase gene and osteoporosis: relationship of ten polymorphic loci with bone mineral density
Riancho, J., Zarrabeitia, M. T., Valero, C., Sañudo, C., Hernández, J. L., Amado, J. A., Zarrabeitia, A., & González-Macías, J. (2005) · Bone · doi:10.1016/j.bone.2005.01.004 · Cited by 53
Hofbauer, L. C., Schoppet, M., Schüller, P., Viereck, V., & Christ, M. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01969.x · Cited by 49
“In postmenopausal women, a positive correlation between circulating OPG levels and oestradiol and between OPG levels and bone mineral density has been described (Rogers et al., 2002), although other studies did not confirm these findings (Yano et al.”
ResultSuh, K. T., Lee, S.-S., Hwang, S. H., Kim, S., & Lee, J. S. (2007) · European Spine Journal · doi:10.1007/s00586-007-0390-2 · Cited by 50
“Although conflicting, however, serum OPG levels show an inverse relationship with BMD in humans [25].”
BackgroundUlrich‐Vinther, M. (2007) · Acta Orthopaedica · doi:10.1080/17453690610046512 · Cited by 51
Samelson, E. J., Broe, K. E., Demissie, S., Beck, T., Karasik, D., Kathiresan, S., & Kiel, D. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2492 · Cited by 49
“In contrast, no association between OPG and femoral neck bone density was found in 304 women in the Rochester Epidemiology Project (12) or 180 women in the European Vertebral Osteoporosis Study (31).”
BackgroundAbrahamsen, B., Hjelmborg, J., Kostenuik, P. J., Stilgren, L. S., Kyvik, K. O., Adamu, S., Brixen, K., & Langdahl, B. L. (2005) · Bone · doi:10.1016/j.bone.2004.12.015 · Cited by 49
Riancho, J. A., Valero, C., Naranjo, Á., Morales-García, D. J., Sañudo, C., & Zarrabeitia, M. T. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1616 · Cited by 46
Grinspoon, S. K., Friedman, A. J., Miller, K. K., Lippman, J., Olson, W. H., & Warren, M. P. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030033 · Cited by 43
“shown between OPG and serum estradiol (37).”
Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women
Messalli, E. M., Mainini, G., Scaffa, C., Cafiero, A. C., Salzillo, P. L., Ragucci, A., & Cobellis, L. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.05.007 · Cited by 42
Banerjee, S. N., Smith, I. E., Folkerd, L., Iqbal, J., Barker, P. N., & Dowsett, M. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi322 · Cited by 42
“Estrogen is also a major determinant of bone turnover with low estradiol levels in postmenopausal women being associated with increased bone turnover [2].”
BackgroundDecrease in the number and apoptosis of alveolar bone osteoclasts in estrogen‐treated rats
Faloni, A. P. S., Sasso‐Cerri, E., Katchburian, E., & Cerri, P. S. (2007) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2006.00932.x · Cited by 40
RANKL/RANK/OPG system and bone status in females with anorexia nervosa
Ostrowska, Z., Ziora, K. T., Oświęcimska, J. M., Świętochowska, E., Szapska, B., Wołkowska-Pokrywa, K., & Dyduch, A. (2011) · Bone · doi:10.1016/j.bone.2011.09.054 · Cited by 39
“study [38] showed a correlation between OPG and BMD increase.”
BackgroundCoulson, J., Bagley, L., Barnouin, Y., Bradburn, S., Butler-Browne, G., Gapeyeva, H., Hogrel, J.-Y., Maden-Wilkinson, T., Maier, A. B., Meskers, C., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4104-2 · Cited by 37
“A study of postmenopausal women of mean age 62 years [20] and a study of middle-agedmen [21] reported inverse relationships between BMD and OPG, while others reported no relationship [22, 23].”
Doumouchtsis, K., Kostakis, A., Doumouchtsis, S. K., Grapsa, E., Passalidou, I., Tziamalis, M. P., Poulakou, M. V., Vlachos, I. S., & Perrea, D. N. (2008) · Hemodialysis International · doi:10.1111/j.1542-4758.2008.00249.x · Cited by 40
RANKL inhibition for the management of patients with benign metabolic bone disorders
Anastasilakis, A. D., Toulis, K. A., Pοlyzos, S. A., & Terpos, E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903048929 · Cited by 39
“Mean increase in hip BMD was 1.6 – 3.6% at 12 and 3.4 – 5.1% at 24 months.”
BackgroundInfluentialTHE CHARCOT FOOT (PIED DE CHARCOT)
Sanders, L. J., & Frykberg, R. G. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04145-4.50019-3 · Cited by 36
Uemura, H., Yasui, T., Miyatani, Y., Yamada, M., Hiyoshi, M., Arisawa, K., & Irahara, M. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03345584 · Cited by 41
The effect of exercise and estrogen on osteoprotegerin in premenopausal women
West, S., Scheid, J. L., & Souza, M. J. D. (2008) · Bone · doi:10.1016/j.bone.2008.09.008 · Cited by 36
“OPG is proving to be important in the pathogenesis of bone loss in postmenopausal women [27,29–33] and underscores the importance of investigating this cytokine in a premenopausal cohort.”
BackgroundHuang, A. J., Ettinger, B. B., Vittinghoff, E., Ensrud, K. E., Johnson, K., & Cummings, S. R. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070707 · Cited by 42
“are associated with clinically significant differences in BMD, bone turnover, bone loss,((5,6,10,17,18)) and fracture risk.”
BackgroundCarlo, C. D., Tommaselli, G. A., Gargano, V., Sammartino, A., Bifulco, G., Tauchmanovà, L., Colao, A., & Nappi, C. (2006) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000227855.04732.7b · Cited by 34
“Other studies have failed to confirm these data.(15,16)”
ResultOh, K. W., Rhee, E., Lee, W., Kim, S. W., Oh, E. S., Baek, K. H., Kang, M. I., Choi, M. G., Yoo, H. J., & Park, S. W. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02090.x · Cited by 36
“Many studies have been reported on female subjects in terms of the association between other biochemical markers of bone turnover and serum OPG levels (Yano et al., 1999; Khosla et al., 2002; Rogers et al., 2002).”
BackgroundHan, K. O., Choi, J. T., Choi, H. A., Moon, I. G., Yim, C. H., Park, W. K., Yoon, H. K., & Han, I. K. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02221.x · Cited by 32
Structural and functional changes in the alveolar bone osteoclasts of estrogen‐treated rats
Faloni, A. P. D. S., Sasso‐Cerri, E., Rocha, F. R. G., Katchburian, E., & Cerri, P. S. (2012) · Journal of Anatomy · doi:10.1111/j.1469-7580.2011.01449.x · Cited by 31
“…osteoclast precursors that fail to fuse during osteoclastogenesis, probably due to the estrogen action on the RANK ⁄ RANKL ⁄ OPG [receptor activator of nuclear factor (NF)-jB ⁄ RANK ligand ⁄ osteoprotegerin] system (Kawamoto et al. 2002; Rogers et al. 2002; Bord et al. 2003; Kanzaki et al. 2006).”
BackgroundMuñoz-Calvo, M. T., Barrios, V., Álvaro, M. T. G. D., Lefort, M., Méndez‐Dávila, C., Argente, J., & de la Piedra, C. (2007) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510601110130 · Cited by 32
“[13] showed high levels of OPG related to high BMD and, according to this study, estradiol and OPG are determinants of bone turnover and BMD in postmenopausal women.”
ResultRoddam, A., Appleby, P. N., Neale, R. Ε., Dowsett, M., Folkerd, E. J., Tipper, S. J., Allen, N. E., & Key, T. J. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0060-z · Cited by 31
Safety Considerations of Adjuvant Therapy in Early Breast Cancer in Postmenopausal Women
Gradishar, W. J. (2005) · Oncology · doi:10.1159/000087282 · Cited by 31
Fortner, R. T., Sarink, D., Schöck, H., Johnson, T., Tjønneland, A. M., Olsen, A., Overvad, K., Affret, A., His, M., Boutron‐Ruault, M., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0786-8 · Cited by 30
“, estradiol [60], progesterone [22]) and OPG in healthy women.”
The novel bone alkaline phosphatase B1x isoform in children with kidney disease
Swolin‐Eide, D., Hansson, S., Larsson, L., & Magnusson, P. (2006) · Pediatric Nephrology · doi:10.1007/s00467-006-0231-2 · Cited by 30
Jørgensen, L., Vik, A., Emaus, N., Brox, J. H., HANSEN, J. ‐., Mathiesen, E. B., & Vestergaard, P. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1035-6 · Cited by 30
“[13] with OPG measurements in 180 postmenopausal women.”
BackgroundResultInfluentialTGFβ inducible early gene-1 directly binds to, and represses, the OPG promoter in osteoblasts
Subramaniam, M., Hawse, J. R., Bruinsma, E. S., Grygo, S. B., Cicek, M., Oursler, M. J., & Spelsberg, T. C. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.171 · Cited by 29
“One study reported that serum OPG levels were increased in osteoporosis and another reported a correlation with bone mineral density [16-18].”
BackgroundEndogenous sex steroids and bone mineral density in healthy Greek postmenopausal women
Lambrinoudaki, I. V., Christodoulakos, G., Aravantinos, L., Antoniou, A. G., Rizos, D., Chondros, C., Kountouris, A., Chrysofakis, G., & Creatsas, G. C. (2005) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-005-0648-x · Cited by 31
“[27], evaluating a large cohort of elderly postmenopausal women, reported that women in the lowest BMD quartile at all sites had significantly lower serum estradiol than did women in the highest BMD quartile.”
BackgroundExtended adjuvant endocrine therapy in early breast cancer: finding the individual balance
Lobo-Martins, S., Arecco, L., Pina-Cabral, T., Agostinetto, E., Dauccia, C., Franzoi, M. A., Mastro, L. D., Lambertini, M., Piccart, M. J., & de Azambuja, E. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105057 · Cited by 27
“60 Consequently, estrogen de fi ciency increases the rate of bone loss leading to osteoporosis and a higher risk of bone fractures.”
Sumida, R., Maeda, T., Kawahara, I., Yusa, J., & Kato, Y. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7560 · Cited by 27
“OPG/RANKL ratio has been reported: Low in immature osteoblasts and high in mature osteoblasts (23,52), suggesting that the PRF‐induced increase in OPG/RANKL ratio is associated with bone formation.”
BackgroundOpg/Rankl mRNA dynamic expression in the bone tissue of ovariectomized rats with osteoporosis
Li, C. W., Liang, B., Shi, X., & Wang, H. (2015) · Genetics and Molecular Research · doi:10.4238/2015.august.10.1 · Cited by 27
Relationship of lumbar spine bone mineral density and oral dryness feeling in menopause
Agha‐Hosseini, F., Mirzaii‐Dizgah, I., & Moosavi, M. (2011) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31820285b2 · Cited by 26
“They can enhance bone resorption and can be suppressed by physiological doses of estrogen.(8,16,17) Today, the administration of estrogen to postmenopausal women was reported to be useful for preventing senile disturbances, specially osteoporosis.”
BackgroundPulsatelli, L., Dolzani, P., Silvestri, T., Caraceni, P., Facchini, A., Ravaglia, G., Salvarani, C., Melicòni, R., & Mariani, E. (2004) · Biogerontology · doi:10.1023/b:bgen.0000025075.04136.ec · Cited by 28
“2002), other workers (Jung et al. 2002; Rogers et al. 2002) did not observe any agerelated variations.”
BackgroundResultSzulc, P., Hawa, G., Boutroy, S., Vilayphiou, N., Schoppet, M., Chapurlat, R. D., & Hofbauer, L. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2617 · Cited by 26
Bauer, M., Bryce, J., & Hadji (2012) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s29432 · Cited by 27
“55–58 Adjuvant endocrine therapy is designed to deprive tumor cells of the growth-promoting effects of estrogen.”
Guañabens, N., Enjuanes, A., Álvarez, L., Peris, P., Caballería, L., de Osaba, M. J. M., Cerdá, D., Monegal, A., Pons, F., & Parés, A. R. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0042-1 · Cited by 28
“observed negative associations between markers of bone turnover and OPG serum levels and a weak positive association with bone density [16].”
BackgroundThe use of biochemical markers in osteoporosis
Hammett‐Stabler, C. A. (2004) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2004.01.013 · Cited by 28
“For women, levels of the various markers increase after the onset of menopause in response to the increased turnover associated with estrogen deficiency [24–29].”
BackgroundGonnelli, S., Montagnani, A., Caffarelli, C., Cadirni, A., Campagna, M. S., Franci, M. B., Lucani, B., Gaggiotti, E., & Nuti, R. (2005) · Journal of Endocrinological Investigation · doi:10.1007/bf03347242 · Cited by 24
Agha‐Hosseini, F., Mirzaii‐Dizgah, I., & Moosavi, M. (2012) · Gerodontology · doi:10.1111/j.1741-2358.2012.00619.x · Cited by 22
Inflammatory bowel diseases as secondary causes of osteoporosis
Bernstein, C. N. (2006) · Current Osteoporosis Reports · doi:10.1007/bf02686956 · Cited by 23
Ho-Pham, L. T., Nguyen, H. G., Nguyen-Pham, S. Q., Hoang, D. K., Tran, T. S., & Nguyen, T. V. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06757-z · Cited by 20
“In postmenopausal women, bone loss is thought to occur in two stages: rapid loss during the first 5 years and gradual loss after 10 years following menopause [1].”
BackgroundMazziotti, G., Amato, G., Sorvillo, F., Piscopo, M., Rizzo, M. R., Lalli, E., Iride, L., Cioffi, M., Molinari, A. M., Paolisso, G., et al. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02099 · Cited by 20
“acts as a decoy receptor, binding RANKL and thereby inhibiting the interaction between RANKL and its receptorontheosteoclastsurface(12).Inhumans,OPGseems to exert aprotective role in postmenopausal osteoporosis (13, 14 ) and other metabolic diseases characterised by bone loss (15, 16).”
BackgroundBone Physiology: Bone Cells, Modeling, and Remodeling
Dempster, D. W., & Raisz, L. G. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2001-3_3 · Cited by 30
Nanoscale Calcium Salt-Based Formulations As Potential Therapeutics for Osteoporosis
Dashnyam, K., Bayaraa, O., Mandakhbayar, N., Park, J.-H., Lee, J., Jang, T., Лувсан, Х., & Kim, H. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00219 · Cited by 20
Amer, O. E., Wani, K., Ansari, M. G. A., Alnaami, A. M., Aljohani, N., Abdi, S., Hussain, S. D., Al‐Daghri, N. M., & Alokail, M. S. (2022) · Medicina · doi:10.3390/medicina58080976 · Cited by 19
“In some studies, BMD was positive, either inversely associated or not correlated with OPG serum levels in postmenopausal women [21,34].”
Stuss, M., Sewerynek, E., Król, I., Stępień-Kłos, W., & Jędrzejczyk, S. (2016) · Endokrynologia Polska · doi:10.5603/ep.a2016.0014 · Cited by 18
“tion markers in urine and PTH concentrations [18].”
BackgroundUemura, H., Yasui, T., Miyatani, Y., Yamada, M., Hiyoshi, M., Arisawa, K., & Irahara, M. (2007) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318046369b · Cited by 17
Quantitative genetics of circulating molecules associated with bone metabolism: a review.
Livshits, G. (2006) · PubMed · Cited by 19
Kim, J. G., Kim, J. H., Lee, D. O., Kim, H., Kim, J. Y., Suh, C. S., Kim, S. H., & Choi, Y. M. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318133a153 · Cited by 18
Pandey, A., Ya, K., Kushwaha, S. S., Mohammed, F., & Verma, A. (2018) · Malaysian Orthopaedic Journal · doi:10.5704/moj.1803.006 · Cited by 17
Protective Effect of Oxytocin Against Bone Loss in a Female Rat Model of Osteoporosis
Moghazy, H. M., Mahmoud, A. A., ElBadre, H. M., & Aziz, H. O. A. (2020) · Reports of Biochemistry and Molecular Biology · doi:10.29252/rbmb.9.2.147 · Cited by 15
“These results were in agreement with those of previous studies (20, 23).”
Result
Metadata
- Authors
- Rogers, A., Saleh, G., Hannon, R. A., Greenfield, D., & Eastell, R.
- Affiliations
- University of Sheffield (GB)
- Sheffield Hallam University (GB)
- Corresponding author
- Rogers, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-10
- Volume
- 87
- Issue
- 10
- Pages
- 4470-4475
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1972546618
- Cited by
- 200
- References
- 20
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 7 · 2021: 3 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 6 · 2014: 3 · 2013: 7 · 2012: 7
- FWCI
- 15.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- estradiol, osteoprotegerin, bone turnover markers, bone mineral density, postmenopausal women, estrogen, bone resorption, bone formation, RANKL, osteoclasts, menopause, hip bone density, femoral neck, lumbar spine, body mass index, age, bone loss prevention, osteoporosis
- MeSH terms
- Aged, Aged, 80 and over, Analysis of Variance, Estradiol, Female, Femur, Glycoproteins, Humans, Lumbar Vertebrae, Middle Aged, Regression Analysis, Biomarkers, Bone Density, Body Mass Index, Bone Remodeling, Postmenopause, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.